Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Sellers Reduced Their Shorts By 19% As Of Jan 12, 2019

Aeglea Biotherapeutics Inc (NASDAQ:AGLE) had a decrease of its shorted shares by 19%. FINRA announced in January AGLE’s total 621,700 shorted shares. The down change of 19% from 767,500 shares was reported. Aeglea Biotherapeutics Inc (NASDAQ:AGLE) has 131,900 shares average volume. It’ll cost 5 days for AGLE to restore its former position. Float short on Aeglea Biotherapeutics Inc is 5.62%.

The stock decreased 0.58% or $0.05 during the last trading session, hitting $8.51.Currently Aeglea BioTherapeutics, Inc. is uptrending after 59.67% change in last January 12, 2018. AGLE has also 54,929 shares volume. The stock outperformed the S&P500 by 59.67%.

Aeglea Biotherapeutics, Inc., a biotechnology company, develops enzyme therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer.The firm is worth $203.76 million. The Company’s human enzymes are designed to degrade specific amino acids in the blood.Last it reported negative earnings. The companyÂ’s lead product candidate, AEB1102 is human Arginase I, engineered to reduce arginine levels to treat patients with Arginase I deficiency and patients with arginine-dependent solid tumors and hematological malignancies.

For more Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) news released briefly go to:,,, or The titles are as follows: “Small healthcare stocks shrug off broad market selling – Seeking Alpha” released on December 07, 2018, “Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock – GlobeNewswire” on April 17, 2018, “Rubius IPO: A Bit Expensive And At An Early Stage – Seeking Alpha” with a publish date: July 11, 2018, “Anika Reports Top Line Data from CINGAL Study, Shares Slump – Nasdaq” and the last “Amgen’s Repatha Reduces Bad Cholestrol in Type II Diabetes – Nasdaq” with publication date: June 25, 2018.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.